Day One Biopharmaceuticals Inc

Day One’s merger with Servier ends public trading; insiders, led by CEO Jeremy Bender, liquidate holdings for cash‑for‑shares, closing the company’s stock and shifting focus to private integration and future prospects.

Day‑one insider RSU buys at Day One Biopharmaceuticals signal executive confidence and reveal routine tax‑planning moves amid a volatile biotech cycle.